In @entity1 with @entity1030 ( @entity1030 ), @entity2057 can occur independently of fat loss, suggesting disturbances in protein metabolism. In order to provide more insight in @entity535 (AA) metabolism in @entity1 with stable @entity1030 , we examined arterial plasma and anterior tibialis muscle AA levels, comparing 12 @entity1030 @entity1 with eight age-matched healthy control subjects. We also studied relationships between AA levels, the acute phase response as measured by @entity5752 ( @entity5752 ), and resting energy expenditure (REE). In contrast to findings in @entity697 associated with @entity2057 , we found increased muscle @entity1160 ( @entity7647 ) levels in our @entity1 group (mean +/- SEM = 10,782 +/- 770 versus 7,844 +/- 293 micromol/kg wet weight, p < 0. 01). Furthermore, muscle @entity369 , @entity7222 , and @entity7792 were significantly increased in the @entity1 group, whereas @entity367 was decreased. In plasma, the sum of all AA (SumAA) was decreased in the @entity1 group (2,595 +/- 65 versus 2,894 +/- 66 micromol/L, p < 0.01), largely because of decreased levels of @entity493 (254 +/- 10 versus 375 +/- 25 micromol/L, p < 0.0001), @entity7647 (580 +/- 17 versus 641 +/- 17 micromol/L, p < 0.05), and @entity367 (91 +/- 5 versus 130 +/- 10 micromol/L, p < 0.01). @entity5752 levels were increased in @entity1030 @entity1 as compared with controls (11.7 +/- 4.5 versus 8.6 +/- 1.0 mg/L, p < 0.05), and showed a positive correlation with REE (r = 0. 49, p = 0.03), a negative correlation with the SumAA in plasma (r = -0.76, p < 0.0001), and no correlation with muscle AA levels. In conclusion, various disturbances in plasma and muscle AA levels were found in @entity1030 @entity1 . A relationship between the observed decreased plasma AA levels and @entity32 was suggested.

Plasma and muscle @entity535 levels in relation to resting energy expenditure and @entity32 in stable XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5752 :: ('3929', 'Gene') :: ['LBP', 'lipopolysaccharide-binding protein'] @entity7792 :: ('CHEBI:16349', 'Chemical') :: ['citrulline'] @entity697 :: ('MESH:D000208', 'Disease') :: ['acute diseases'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity1160 :: ('CHEBI:28300', 'Chemical') :: ['glutamine'] @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino-acid'] @entity7222 :: ('CHEBI:18257', 'Chemical') :: ['ornithine'] @entity7647 :: ('CHEBI:32668', 'Chemical') :: ['GLN'] @entity367 :: ('CHEBI:18237', 'Chemical') :: ['glutamic acid'] @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive pulmonary disease', 'COPD'] @entity2057 :: ('MESH:D009133', 'Disease') :: ['muscle wasting'] @entity493 :: ('CHEBI:16449', 'Chemical') :: ['alanine'] @entity369 :: ('CHEBI:29016', 'Chemical') :: ['arginine']
@entity1030 :: (MESH:D029424,Disease) :: ['chronic obstructive pulmonary disease']
